24/7 Market News Snapshot 26 December, 2024 – Hoth Therapeutics, Inc. Common Stock (NASDAQ:HOTH)

December 26, 2024

DENVER, Colo., 26 December, 2024 (247marketnews.com) – (NASDAQ:HOTH) are discussed in this article.
Hoth Therapeutics, Inc. is navigating a challenging market environment, facing a notable decline in stock price, which opened at $0.81 and subsequently traded at $0.733, reflecting a decrease of approximately -6.86%. The closing price from the previous session was $0.787, indicating ongoing selling pressure. With a current trading volume of 7.31 million shares, investor engagement remains high; however, the bearish trend signals diminished confidence in the immediate future. Potential support levels are around $0.70, while resistance appears to rest at $0.80. Market observers are advised to closely monitor trading volume and price movements to assess opportunities for reversals or further declines in this biotech firm.

Simultaneously, Hoth Therapeutics has made significant strides in its therapeutic pipeline. The company has entered into an exclusive patent license agreement with the U.S. Department of Veterans Affairs and Emory University, securing exclusive rights to a joint patent portfolio targeting “Glial Cell Line-Derived Neurotrophic Factor, Obesity, and Obesity-Related Diseases and Conditions.” This landmark agreement reinforces Hoth’s commitment to developing innovative solutions aimed at addressing obesity and its related health challenges.

Robb Knie, the CEO of Hoth Therapeutics, expressed optimism regarding this collaboration, emphasizing its potential to enhance the development and accessibility of crucial therapeutic options. The company aims to effectively translate this patented technology from research phases into practical applications that meet pressing healthcare needs.

Additionally, Hoth has signed a Letter of Intent to expand its intellectual property portfolio, which includes acquiring provisional patent protection for its key therapeutic candidate, HT-001. This strategic move underscores Hoth’s dedication to broadening its treatment offerings and addressing unmet medical needs within the biopharmaceutical industry.

Related news for (HOTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.